Unanswered questions following reports of secondary malignancies after CAR-T cell therapy.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 38195751.
- Also identified by DOI 10.1038/s41591-023-02767-w and PMC identifier 11688691.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Reports of T cell malignancies after CAR-T cell therapy should be investigated, but existing data from follow-up studies suggest a low risk compared with other cancer treatments.
Medical subject headings
- Receptors, Chimeric Antigen
- Lymphoma, B-Cell
- Hematologic Neoplasms